We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+50.68%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$548M
AUM Growth
+$192M
Cap. Flow
+$43.1M
Cap. Flow %
7.87%
Top 10 Hldgs %
43.03%
Holding
102
New
19
Increased
25
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$28M
2
LIAN
LianBio American Depositary Shares
LIAN
+$10.7M
3
NUVL
Nuvalent
NUVL
+$7.74M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.35M
5
ALKS icon
Alkermes
ALKS
+$6.66M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$10.2M
2
KURA icon
Kura Oncology
KURA
+$6.54M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.41M
4
PRTA icon
Prothena Corp
PRTA
+$3.82M
5
KRYS icon
Krystal Biotech
KRYS
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
1
DELISTED
Immunogen Inc
IMGN
$41.6M 7.61%
+1,404,608
New +$28M
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$31.8M 5.81%
750,000
+64,939
+9% +$1.87M
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
$25.8M 4.7%
1,090,441
-38,935
-3% -$693K
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.8B
$23.1M 4.23%
100,000
+15,000
+18% +$2.62M
XENE icon
5
Xenon Pharmaceuticals
XENE
$6.6B
$21.2M 3.87%
460,000
+159,562
+53% +$5.64M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$37.3B
$19.8M 3.62%
1,900,000
-100,000
-5% -$934K
ACLX
7
DELISTED
Arcellx
ACLX
$18.9M 3.45%
340,000
-60,000
-15% -$2.71M
LIAN
8
DELISTED
LianBio American Depositary Shares
LIAN
$16.9M 3.09%
3,779,694
+3,107,337
+462% +$10.7M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$15.9M 2.91%
447,095
-2,905
-0.6% -$89.1K
CLDX icon
10
Celldex Therapeutics
CLDX
$2.77B
$15.9M 2.9%
400,000
+250,000
+167% +$7.35M
APGE icon
11
Apogee Therapeutics
APGE
$10.1B
$15M 2.74%
537,093
-508,017
-49% -$10.2M
TEVA icon
12
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$14.6M 2.67%
1,400,000
+300,000
+27% +$2.8M
IMVT icon
13
Immunovant
IMVT
$8.27B
$14.5M 2.65%
345,000
+45,000
+15% +$1.66M
CYTK icon
14
Cytokinetics
CYTK
$10.9B
$13.4M 2.44%
160,000
-70,366
-31% -$2.55M
NUVL
15
DELISTED
Nuvalent
NUVL
$12.9M 2.35%
175,000
+125,000
+250% +$7.74M
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$11.3M 2.06%
1,466,465
+466,165
+47% +$2.58M
VRNA
17
DELISTED
Verona Pharma
VRNA
$11.2M 2.05%
563,824
+195,495
+53% +$2.89M
SYRE icon
18
Spyre Therapeutics
SYRE
$8.7B
$11.1M 2.03%
517,554
+275,257
+114% +$3.79M
AUTL
19
Autolus Therapeutics
AUTL
$383M
$9.98M 1.82%
1,550,408
-442,058
-22% -$1.69M
ALKS icon
20
Alkermes
ALKS
$8.79B
$9.89M 1.81%
356,384
+256,384
+256% +$6.66M
INZY
21
DELISTED
Inozyme Pharma
INZY
$8.03M 1.47%
1,885,802
+505,950
+37% +$1.8M
EYPT icon
22
PUT
EyePoint Inc
EYPT
$1.12B
$7.4M 1.35%
320,100
+165,100
+107% +$1.85M
NRIX icon
23
Nurix Therapeutics
NRIX
$2.4B
$7.12M 1.3%
690,112
+440,112
+176% +$3.02M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$6.33M 1.16%
795,729
-222,362
-22% -$1.49M
ESTA icon
25
Establishment Labs
ESTA
$2.72B
$5.91M 1.08%
228,277
-10,831
-5% -$317K
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Affinity Asset Advisors held 102 positions worth $548M, up 54% from $356M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $43.1M of net new capital in Q4 2023, opening 19 new positions and adding to 25 existing holdings. Its largest new stake was Immunogen Inc: 1,404,608 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Apogee Therapeutics, an estimated $10.2M trimmed.

  • Affinity Asset Advisors's largest Q4 2023 buy was Immunogen Inc: 1,404,608 shares worth $41.6M.
  • Affinity Asset Advisors added most to LianBio American Depositary Shares in Q4 2023, an estimated $10.7M increase.
  • Affinity Asset Advisors's biggest Q4 2023 reduction was Apogee Therapeutics, cutting an estimated $10.2M.
  • Affinity Asset Advisors fully exited Prothena Corp in Q4 2023, selling an estimated $3.82M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $548M portfolio in Q4 2023.
  • Affinity Asset Advisors opened 19 new positions and closed 20 in Q4 2023.
  • Affinity Asset Advisors's portfolio value rose 54% quarter-over-quarter to $548M.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.